Pharmaceutical News

RSS

FDA ODAC votes in favour of GSK's Votrient

GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial.

21 Mar 2012

Study shows how to defeat chemotherapy barrier in pancreatic cancer

Scientists at Fred Hutchinson Cancer Research Center and the Translational Genomics Research Institute (TGen) have discovered a literal 'break through' in pancreatic cancer.

21 Mar 2012

Top scientific experts publish new TB vaccine Blueprint

Against a backdrop of growing concern about the impact of tuberculosis on children, top scientific experts today published a global plan of action for developing the vaccines that are seen as critical to eliminating the disease.

21 Mar 2012

Common pain relievers could cause hypertension

Diseases such as kidney failure and endocrine tumors are among the suspects causing high blood pressure - but could the common pain relievers in your medicine cabinet be the culprit? According to Prof. Ehud Grossman of Tel Aviv University's Sackler Faculty of Medicine and the Sheba Medical Center, many common over-the-counter and prescription medications are underlying causes of hypertension, which is a major risk factor for stroke, heart attack, and aneurisms.

21 Mar 2012

IDSA releases new rhinosinusitis guidelines

The vast majority of sinus infections are caused by viruses and should not be treated with antibiotics, suggest new guidelines released by the Infectious Diseases Society of America.

21 Mar 2012

Curcumin can help prevent clumping of proteins in Parkinson's

Curcumin, a compound found in the spice turmeric, is proving effective at preventing clumping of a protein involved in Parkinson's disease, says a Michigan State University researcher.

21 Mar 2012

Meda's Astepro receives registration approval in Europe

Astepro has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis.

21 Mar 2012

FDA approves Watson's generic BONIVA ANDA to treat osteoporosis in women

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc. has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Ibandronate 150mg tablets, the generic equivalent to Roche's BONIVA tablets.

21 Mar 2012

Lexicon receives FDA Orphan Drug designation for telotristat etiprate to treat carcinoid syndrome

Lexicon Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome.

21 Mar 2012

Mylan receives final FDA approval for generic Boniva ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ibandronate Sodium Tablets, 150mg.

20 Mar 2012

Ampio receives U.S. patent allowance for lead drug Ampion

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs, licensing distribution of these drugs and engaged in further drug development, today announced that it has received notice of allowance from the US Patent Office of an additional patent that complements and expands its anti inflammatory patent portfolio for its lead drug Ampion.

20 Mar 2012

Pediatricians' unconscious racial bias may affect pain medication decisions

Pediatricians who show an unconscious preference for European Americans tend to prescribe better pain-management for white patients than they do for African-American patients, new University of Washington research shows.

20 Mar 2012

New antibiotic shows promise against bovine mastitis

Food-borne diseases might soon have another warrior to contend with, thanks to a new molecule discovered by chemists at the University of Illinois. The new antibiotic, an analog of the widely used food preservative nisin, also has potential to be a boon to the dairy industry as a treatment for bovine mastitis.

20 Mar 2012

FHCRC research represents potential breakthrough in treatment of pancreas cancer

Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreas cancer.

20 Mar 2012

Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC, the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development.

20 Mar 2012

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

20 Mar 2012

Gilenya - pill for relapsing-remitting multiple sclerosis recommended by NICE

The National Institute for Health and Clinical Excellence (Nice) issued new draft guidance recommending fingolimod (brand name Gilenya) on the NHS for some patients with a form of MS. The new drug can help reduce the number of relapses in adults with highly active relapsing-remitting multiple sclerosis (RRMS), which is characterized by periods when symptoms worsen and then improve.

19 Mar 2012

$Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015$

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

19 Mar 2012

Soy-based S-equol lowers HbA1c, LDL cholesterol and improves vascular stiffness

A 12-week treatment of the fermented soy germ-based nutritional supplement containing S-equol significantly lowered hemoglobin A1c (HbA1c), LDL cholesterol and improved vascular stiffness, all factors that occur as part of metabolic syndrome, according to a first-of-its-kind peer-reviewed study reported in a poster at the Women's Health 2012 annual meeting.

19 Mar 2012

Merz launches new, once daily Mederma Advanced Scar Gel

Mederma, the #1 doctor-and pharmacist-recommended brand for scars for over a decade, announced today the introduction of Mederma Advanced Scar Gel, which reduces the overall appearance of scars caused by injury, acne, surgery or burns with just one daily application. Mederma Advanced Scar Gel contains Cepalin, the same proprietary botanical extract derived from onions used in all Mederma® scar products and stretch marks therapy.

19 Mar 2012